The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.
Status:
Not yet recruiting
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
This study is a prospective study. We signed an informed consent form with patients with
liver fibrosis and took tauroursodeoxycholic acid orally for half a year. After half a year,
liver biopsy was performed using histopathology, immunohistochemistry, and polymerase chain
reaction, Western blotting method was used to determine the expression level of
fibrosis-related markers to verify the effect of taurodeoxycholic acid on patients with liver
fibrosis.
Phase:
Early Phase 1
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University